NCT01795677View on ClinicalTrials.gov

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

March 31, 2019

Conditions
Myelofibrosis
Interventions
DRUG

Ruxolotinib

Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor

Trial Locations (1)

75010

ROBIN, Paris

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT01795677 - JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter